| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Radiology, Vol 169, 117-122, Copyright © 1988 by Radiological Society of North America
ARTICLES |
RI Grossman, BH Braffman, JR Brorson, HI Goldberg, DH Silberberg and F Gonzalez- Scarano
Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia 19104.
Thirteen patients with definite multiple sclerosis (MS), studied 16-24 months previously with magnetic resonance (MR) imaging with and without enhancement by intravenously administered gadolinium diethylenetriaminepentaacetic acid (DTPA) dimeglumine, were reexamined with a similar protocol. Assessment of enhancement and clinical activity in both studies revealed that enhancement was observed in 13 of 14 cases in which clinical activity had changed within 4 weeks of the study and thus appeared more sensitive than clinical examination in determining active disease. The 3-minute postinjection, short repetition time image (TR) was the most efficient for depicting enhancement. Enhancing lesions (active plaques) arose from previously hyper- or isointense regions on long TR images. Previously active lesions reverted to areas of iso- or hyperintensity on long TR images. Serial comparison of long TR images in this population reveals a decrease in high-intensity lesions on long TR images in some cases and an increase in others. The findings of high-intensity regions on long TR images and previously enhancing lesions both becoming isointense suggests that transient inflammatory changes with concomitant edema without demyelination and/or with significant remyelination may occur in some MS lesions. MS lesions are dynamic; both active and inactive lesions may show dramatic change on longitudinal MR imaging studies.
This article has been cited by other articles:
|
|
 |
|
  M. M. Vellinga, R. D. Oude Engberink, A. Seewann, P. J.W. Pouwels, M. P. Wattjes, S. M.A. van der Pol, C. Pering, C. H. Polman, H. E. de Vries, J. J.G. Geurts, et al. Pluriformity of inflammation in multiple sclerosis shown by ultra-small iron oxide particle enhancement Brain, March 1, 2008; 131(3): 800 - 807. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Ge Multiple Sclerosis: The Role of MR Imaging AJNR Am. J. Neuroradiol., June 1, 2006; 27(6): 1165 - 1176. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Dousset, B. Brochet, M.S.A. Deloire, L. Lagoarde, B. Barroso, J.-M. Caille, and K.G. Petry MR Imaging of Relapsing Multiple Sclerosis Patients Using Ultra-Small-Particle Iron Oxide and Compared with Gadolinium. AJNR Am. J. Neuroradiol., May 1, 2006; 27(5): 1000 - 1005. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Barkhof, U. Held, J. H. Simon, M. Daumer, F. Fazekas, M. Filippi, J. A. Frank, L. Kappos, D. Li, S. Menzler, et al. Predicting gadolinium enhancement status in MS patients eligible for randomized clinical trials Neurology, November 8, 2005; 65(9): 1447 - 1454. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Cotton, H. L. Weiner, F. A. Jolesz, and C. R.G. Guttmann MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals Neurology, February 25, 2003; 60(4): 640 - 646. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Brod, J. W. Lindsey, F. S. Vriesendorp, C. Ahn, E. Henninger, P. A. Narayana, and J. S. Wolinsky Ingested IFN-{alpha}: Results of a pilot study in relapsing-remitting MS Neurology, September 11, 2001; 57(5): 845 - 852. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Poser Trauma to the Central Nervous System May Result in Formation or Enlargement of Multiple Sclerosis Plaques Arch Neurol, July 1, 2000; 57(7): 1074 - 1077. [Full Text] [PDF]
|
|
|
|
|
|
A. J. Barkovich Concepts of Myelin and Myelination in Neuroradiology AJNR Am. J. Neuroradiol., June 1, 2000; 21(6): 1099 - 1109. [Full Text]
|
|
|
|
|
|
Y. Ge, R. I. Grossman, J. K. Udupa, J. Fulton, C. S. Constantinescu, F. Gonzales-Scarano, J. S. Babb, L. J. Mannon, D. L. Kolson, and J. A. Cohen Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: Quantitative MR assessment Neurology, February 22, 2000; 54(4): 813 - 817. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A M Rostami, R A Sater, S J Bird, S Galetta, R E Farber, M Kamoun, D H Silberberg, R I Grossman, and D Pfohl A double-blind, placebo-controlled trial of extracorporeal photopheresis in chronic progressive multiple sclerosis Multiple Sclerosis, June 1, 1999; 5(3): 198 - 203. [Abstract] [PDF]
|
|
|
|
 |
|
 Y. Miki, R. I. Grossman, J. K. Udupa, M. A. van Buchem, L. Wei, M. D. Phillips, U. Patel, J. C. McGowan, and D. L. Kolson Differences between Relapsing-Remitting and Chronic Progressive Multiple Sclerosis as Determined with Quantitative MR Imaging Radiology, March 1, 1999; 210(3): 769 - 774. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. J. Khoury and H. L. Weiner Multiple Sclerosis: What Have We Learned From Magnetic Resonance Imaging Studies? Arch Intern Med, March 23, 1998; 158(6): 565 - 573. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N Tubridy, H J Ader, F Barkhof, A J Thompson, and D H Miller Exploratory treatment trials in multiple sclerosis using MRI: sample size calculations for relapsing-remitting and secondary progressive subgroups using placebo controlled parallel groups J. Neurol. Neurosurg. Psychiatry, January 1, 1998; 64(1): 50 - 55. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| RADIOLOGY | RADIOGRAPHICS | RSNA JOURNALS ONLINE |
